Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …

Survivors of childhood, adolescent, and young adult cancer, previously treated with
anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was …

Importance Anthracyclines are part of many effective pediatric cancer treatment protocols.
Most pediatric oncology treatment groups assume that the hematologic toxicity of …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Objective To investigate the impact of modifications to contemporary cancer protocols, which
minimize exposures to cardiotoxic treatments and preserve long term health, on serious …

Cardiac diseases in the growing population of childhood cancer survivors are of major
concern. Cardiotoxicity as a consequence of anthracyclines and chest radiotherapy …

Survivors of childhood cancer are at risk of anthracycline-induced cardiotoxicity, which might
be prevented by dexrazoxane. However, concerns exist about the safety of dexrazoxane …

Over the last decades, childhood and adolescence have emerged as an important window
of opportunity to prevent atherosclerotic cardiovascular disease (ASCVD) later in life. Here …

Importance Chemotherapy during the first trimester of pregnancy should be avoided owing
to the risk of congenital malformations. However, the precise gestational age at which …

Purpose We sought to assess the impact of disruptions due to coronavirus disease 2019
(COVID‐19) on caregivers of childhood cancer survivors. Methods A 13‐question survey …